Alnylam Pharmaceuticals, Inc. (ALNY) scores 65 out of 100 on boothcheck's 11-model valuation framework. Verdict: Fair The estimated fair value is 306.59, representing a 7% premium to fair value. Quantitative score: 60/100. Qualitative score: 90/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.